Stanford S. Jhee

The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer’s disease patients

Matthew Kennedy, Andrew W. Stamford, Xia Chen et al. · Science Translational Medicine · 2016 · 407 citations

Glucose Homeostasis, Bace1 Inhibitor Verubecestat, Enzyme 1 +20

Robust Central Reduction of Amyloid-β in Humans with an Orally Available, Non-Peptidic β-Secretase Inhibitor

Patrick C. May, Robert A. Dean, Stephen L. Lowe et al. · Journal of Neuroscience · 2011 · 365 citations · Full text

Robust Central Reduction, Amyloid-β Peptide, Neurochemical Biomarkers +21

The Potent BACE1 Inhibitor LY2886721 Elicits Robust Central Aβ Pharmacodynamic Responses in Mice, Dogs, and Humans

Patrick C. May, Brian A. Willis, Stephen L. Lowe et al. · Journal of Neuroscience · 2015 · 195 citations · Full text

Amyloid β, Neurodegenerative Diseases, Amyloid Lowering +15

The effect of LCZ696 (sacubitril/valsartan) on amyloid‐β concentrations in cerebrospinal fluid in healthy subjects

Thomas Langenickel, Chiaki Tsubouchi, Surya Ayalasomayajula et al. · British Journal of Clinical Pharmacology · 2015 · 109 citations · Full text

Estimation of the Absolute Bioavailability of Rivastigmine in Patients with Mild to Moderate Dementia of the Alzheimer???s Type

Mohammad Sharif Hossain, Stanford S. Jhee, Thomas Shiovitz et al. · Clinical Pharmacokinetics · 2002 · 59 citations

Neurodegenerative Diseases, Alzheimer's Disease, Geriatrics +11